Abstract 212P
Background
The aim of this study was to evaluate the presentation of invasive mammary neoplasms on 18-FDG PET-CT exams, using a breast specific protocol, in prone position, and to correlate the results with histopathological findings and MRI findings.
Methods
Retrospective unicentric analysis of patients with invasive breast carcinoma confirmed by percutaneous biopsy in the staging phase who underwent 18F-FDG PET-CT with breast-specific protocol from September 2012 to April 2019 was performed. Results were correlated with the findings of breast MRI and anatomopathological results. Lesions were evaluated for the maximum standardized uptake value (SUV) on PET-CT, their presentation morphology on MRI and their immunophenotype on immunohistochemical analysis (luminal, HER2 and triple-negative).
Results
The study included 125 patients with a median age of 52 years (24-90 years). The primary tumour presented increased 18F-FDG concentration in PET-CT in 122 cases (97.6%). The mean maximum SUV value of these lesions was 7.24 (1.0-32.9). The mean maximum SUV was higher in tumours with a triple negative immunophenotype (11.4; n = 24) when compared to luminal tumours (6.2; n = 89) and HER2 (5.0; n = 9), P <0.01. Of the included patients, 101 had MRI at diagnosis; the primary tumour presented at MRI as a nodule in 71 cases (70.3%) and as a non-nodular lesion in 30 cases (29.7%). The mean maximum SUV was higher in tumours that presented as a nodule on MRI (8.3 x 4.4; p <0.01). Patients with SUV up to 7 had higher survival rates than those with SUV greater than 7 (85.83 versus 71.35 months, P = 0.03.).
Conclusions
Maximum SUV values obtained on PET-CT with a specific breast protocol correlate with tumour presentation on MRI and tumour immunophenotype and may be used as a prognostic biomarker in patients with invasive breast carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.A. De Mello: Speaker Bureau/Expert testimony: Astellas; Speaker Bureau/Expert testimony: Merck Group; Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy: MSD. All other authors have declared no conflicts of interest.